glp 1 drugs and vision loss Sudden or blurring while taking GLP-1s should be treated as a medical emergency, an expert told Newsweek Emerging Concerns: GLP-1 Modulators and
Description
Cuttica CM, Briata IM, DeCensi A

PMID 24112036

Today, fewer than 1 in 10 people who could benefit from a GLP-1 are taking one, held back by access, stigma, perceived complexity or the belief that their condition isnt serious enough for treatment, said David A Ricks, chair and CEO of Eli Lilly, in a statement

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet

Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial

These agents have been shown to reduce A1C (by 0.81.6%), body weight (by 13 kg), blood pressure, and lipids
